[HTML][HTML] Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline

HS Rugo, RB Rumble, E Macrae… - Journal of Clinical …, 2016 - scholarship.miami.edu
… Khatcheressian, Virginia Cancer Institute, Richmond, VA; Erin Macrae, Columbus Oncology
and Hematology Associates, Columbus, OH; Debra L. Barton, University of Michigan School …

[HTML][HTML] Endocrine treatment and targeted therapy for hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: ASCO …

…, LA Korde, JK Litton, ER Macrae… - Journal of clinical …, 2021 - ncbi.nlm.nih.gov
… Litton, MD, 9 Erin R. Macrae, MD, 10 Lindsay L. Peterson, MD, MSCR, 11 Praveen Vikas,
MBBS, 12 Rachel L. Yung, MD, 13 and Hope S. … Rugo HS, Rumble RB, Macrae E, et al.Endocrine …

[HTML][HTML] Dabrafenib and trametinib in patients with tumors with BRAFV600E mutations: results of the NCI-MATCH trial subprotocol H

AKS Salama, S Li, ER Macrae, JI Park… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE BRAF V600 mutations are commonly found in melanoma and thyroid cancers
and to a lesser degree in other tumor types. Subprotocol H (EAY131-H) of the NCI-MATCH …

[HTML][HTML] Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients

…, M Berger, B Ramaswamy, ER Macrae… - Breast Cancer …, 2014 - Springer
Introduction Circulating tumor cells (CTCs) are commonly isolated from the blood by
targeting the epithelial cell adhesion molecule (EpCAM) through positive selection. However, …

Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer

…, R Layman, B Ramaswamy, ER Macrae… - Cancer Immunology …, 2017 - Springer
This study sought to evaluate whether myeloid-derived suppressor cells (MDSC) could be
affected by chemotherapy and correlate with pathologic complete response (pCR) in breast …

Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast …

M Hicks, ER Macrae, M Abdel-Rasoul, R Layman… - The …, 2015 - academic.oup.com
Background. Randomized clinical trials (RCT) that evaluated the addition of lapatinib to
trastuzumab plus neoadjuvant chemotherapy (NAC) in patients with HER2-positive, operable …

Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy

DSE Seah, IV Luis, E Macrae, J Sohl, G Litsas… - Journal of the National …, 2014 - jnccn.org
Benefits of chemotherapy vary in patients with metastatic breast cancer (MBC). This article
describes the impact of tumor subtype and the line of therapy on the duration of chemotherapy…

Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer

DR Oostra, ER Macrae - Breast Cancer: Targets and Therapy, 2014 - Taylor & Francis
Trastuzumab is a monoclonal antibody that is used in the treatment of breast cancer.
Trastuzumab targets the human epidermal growth factor receptor 2 (HER2) receptor on breast …

Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F] …

…, M Zhao, E Mrozek, RM Layman, E Macrae… - The …, 2020 - academic.oup.com
Background Poly(ADP‐ribose) polymerase inhibitors (PARPis) are US Food and Drug
Administration (FDA) approved for treatment of BRCA‐mutated metastatic breast cancer. …

Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction

…, K Shaver, G Phillips, R Layman, E Macrae… - Supportive Care in …, 2015 - Springer
Purpose Paclitaxel-based chemotherapy continues to be an integral component of breast
cancer treatment. Prolonged use of paclitaxel may result in repeated doses of premedications …